Suppr超能文献

结直肠癌中非精原细胞瘤性睾丸癌幸存者中错配修复基因的体细胞突变。

Somatic hits in mismatch repair genes in colorectal cancer among non-seminoma testicular cancer survivors.

机构信息

Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.

Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.

出版信息

Br J Cancer. 2022 Nov;127(11):1991-1996. doi: 10.1038/s41416-022-01972-7. Epub 2022 Sep 10.

Abstract

BACKGROUND

Non-seminoma testicular cancer survivors (TCS) have an increased risk of developing colorectal cancer (CRC) when they have been treated with platinum-based chemotherapy. Previously we demonstrated that among Hodgkin lymphoma survivors (HLS) there is enrichment of rare mismatch repair (MMR) deficient (MMRd) CRCs with somatic hits in MMR genes. We speculate that this phenomenon could also occur among other cancer survivors. We therefore aim to determine the MMR status and its underlying mechanism in CRC among TCS (TCS-CRC).

METHODS

Thirty TCS-CRC, identified through the Dutch pathology registry, were analysed for MMR proteins by immunohistochemistry. Next-generation sequencing was performed in MMRd CRCs without MLH1 promoter hypermethylation (n = 4). Data were compared with a male cohort with primary CRC (P-CRC, n = 629).

RESULTS

MMRd was found in 17% of TCS-CRCs vs. 9% in P-CRC (p = 0.13). MMRd was more often caused by somatic double or single hit in MMR genes by mutation or loss of heterozygosity in TCS-CRCs (3/30 (10%) vs. 11/629 (2%) in P-CRCs (p < 0.01)).

CONCLUSIONS

MMRd CRCs with somatic double or single hit are more frequent in this small cohort of TCS compared with P-CRC. Exposure to anticancer treatments appears to be associated with the development of these rare MMRd CRC among cancer survivors.

摘要

背景

接受铂类化疗的非精原细胞瘤睾丸癌幸存者(TCS)罹患结直肠癌(CRC)的风险增加。此前,我们证明在霍奇金淋巴瘤幸存者(HLS)中,存在大量错配修复(MMR)缺陷(MMRd)CRC,这些 CRC 存在 MMR 基因的体细胞突变。我们推测这种现象也可能发生在其他癌症幸存者中。因此,我们旨在确定 TCS(TCS-CRC)中 CRC 中的 MMR 状态及其潜在机制。

方法

通过荷兰病理登记处确定了 30 例 TCS-CRC,通过免疫组织化学分析 MMR 蛋白。在没有 MLH1 启动子甲基化的 MMRd CRC 中进行了下一代测序(n=4)。将数据与男性原发性 CRC(P-CRC,n=629)队列进行比较。

结果

TCS-CRC 中发现 MMRd 占 17%,而 P-CRC 中为 9%(p=0.13)。TCS-CRC 中 MMRd 更常由 MMR 基因的体细胞双或单突变或杂合性丢失引起(3/30(10%)比 P-CRC 中的 11/629(2%)(p<0.01))。

结论

与 P-CRC 相比,该小队列的 TCS 中存在更多 MMRd CRC 具有体细胞双或单突变。抗癌治疗的暴露似乎与这些罕见的 MMRd CRC 在癌症幸存者中的发生有关。

相似文献

本文引用的文献

6
The mutational footprints of cancer therapies.癌症治疗的突变足迹。
Nat Genet. 2019 Dec;51(12):1732-1740. doi: 10.1038/s41588-019-0525-5. Epub 2019 Nov 18.
9
Premature Aging in Young Cancer Survivors.年轻癌症幸存者的早衰。
J Natl Cancer Inst. 2019 Mar 1;111(3):226-232. doi: 10.1093/jnci/djy229.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验